Candel Therapeutics CFO Schoch employment agreement keeps base salary at $468,600, bonus target 40%

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00

  • Candel Therapeutics entered an employment agreement on June 12, 2026 with CFO Charles Schoch, keeping his role on an at-will basis.
  • Annual base salary stays at $468,600; annual bonus target remains 40% of base salary.
  • Termination without cause or for good reason triggers 9 months of base salary plus target bonus, paid over 9 months.
  • Company-paid health premium support continues for up to 9 months under COBRA, subject to eligibility limits.
  • Time-based equity awards fully accelerate if termination occurs within 1 month before or 12 months after a change in control.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001841387-26-000007), on June 16, 2026, and is solely responsible for the information contained therein.